Clinical trials
Lung clinical trials
Below are recruiting lung clinical trials, each written for real people, not researchers. We’re tracking 2,828 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07225257Recruiting
Recovering Physical Function After ICU Stay in Older Adults
This study looks at how to help older adults regain physical strength after a serious illness that required time in the ICU. It aims to find the best ways to help you recover daily activities like walking and moving around.
Lexington, KentuckyAges 18–99 - NCT07227077Recruiting
Physical activity study for older cancer survivors with chronic pain
This study uses a smartphone program to encourage physical activity in older adults who have survived cancer and have ongoing pain. It aims to learn how to best help you move more and feel better.
Milwaukee, WisconsinAges 65 years+ - NCT07225036Recruiting
Low-dose liver radiation to boost immunotherapy
This trial tests whether adding a low dose of radiation to the liver can make standard immunotherapy work better for people with non-small cell lung cancer or melanoma that has spread to the liver.
Cincinnati, OhioAges 18 years+ - NCT07223424RecruitingPhase 2
Patient preference study: shot vs infusion for immunotherapy
This study compares two ways to take immunotherapy drugs (nivolumab or pembrolizumab): as a shot under the skin (subcutaneous) versus an infusion into a vein (intravenous). It looks at which method patients prefer and is for people with certain advanced cancers where these drugs are already approved.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
San Diego, CaliforniaAges 18 years+ - NCT07223047RecruitingPhase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Baltimore, MarylandAges 18 years+ - NCT07227376Recruiting
Collecting lung sounds with Eko digital devices
This study uses a digital stethoscope to record lung sounds from patients with and without breathing problems. It aims to help doctors better identify different types of lung sounds.
Jacksonville, FloridaAges Any age - NCT05544240RecruitingPhase 1
First-in-human immunotherapy study for advanced solid tumors
This Phase 1 trial tests SYNC-T, an immunotherapy, in people with advanced or metastatic solid cancers. It aims to find the safest dose and see whether the treatment can shrink or control tumors.
Mexico CityAges 18 years+ - NCT07216105RecruitingPhase 1
New immune cell treatment for advanced solid tumors
This trial tests a new treatment using specially engineered immune cells (called FT836) for people with advanced solid tumors that have not responded to other treatments. It may be given alone or with chemotherapy and/or other antibody medicines. The study aims to see if this approach can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT07217171RecruitingPhase 1
Study of EVOLVE104 for advanced bladder and squamous cell cancers
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
Duarte, CaliforniaAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT07217301RecruitingPhase 3
Comparing TAK-928 to docetaxel for advanced lung cancer
This study tests a new drug called TAK-928 against the standard chemo docetaxel for people with advanced squamous non-small cell lung cancer. You may be able to join if you have already tried a checkpoint inhibitor and platinum chemotherapy, and your cancer has grown.
Jonesboro, ArkansasAges 18 years+ - NCT06917196Recruiting
Inhaled imatinib for advanced lung disease before or after transplant
This trial tests whether a special inhaled form of the medicine imatinib can help people with advanced lung scarring or high blood pressure in the lungs. It is designed for those who are on the path to a lung transplant or already received one.
Pavia, PaviaAges 18 years+ - NCT07219576RecruitingPhase 1/Phase 2
Study of Retifanlimab and Ruxolitinib for Certain Cancers
This trial tests a combination of two drugs, retifanlimab and ruxolitinib, for people with advanced kidney cancer (clear cell renal cell carcinoma) or lung cancer (non-small cell lung carcinoma) whose cancer has grown after previous treatment with a type of immunotherapy called PD-1/PD-L1 inhibitors. The goal is to see if this combination can help when standard treatments are no longer working.
La Jolla, CaliforniaAges Any age - NCT07213375RecruitingPhase 2/Phase 3
High-dose steroid to reduce pain after lung surgery
This trial tests if a high dose of dexamethasone (a steroid) can lower pain after keyhole lung surgery. If you are having planned keyhole lung surgery for a lobe or segment, you may be eligible.
Copenhagen, CopenhagenAges 18 years+ - NCT07214441Enrolling by invitation
BE+ program for lung cancer survivors
This trial tests a program called BE+ for people who have finished treatment for non-small cell lung cancer. It aims to see if the program is practical and helpful for improving health after treatment.
Columbia, South CarolinaAges 21 years+ - NCT06077019Recruiting
How lung function affects exercise in fit adults
This study looks at how your lung function may limit your exercise capacity, even if you are very active. If you are a healthy, highly fit adult aged 18-39, you may be able to help researchers better understand this connection.
CopenhagenAges 18–39 - NCT06621563RecruitingPhase 1
Study of HS-20117 Combination Therapy for Advanced Solid Tumors
This early-phase trial tests a new drug (HS-20117) combined with other drugs for people with advanced solid tumors. It aims to see if the combination is safe and effective, especially for cancers that have not responded to other treatments.
TianjinAges 18–75 - NCT06611527Recruiting
Breathing therapy to improve lung function after heart surgery
This study tests a breathing treatment using mild air pressure after heart surgery to help your lungs work better and reduce complications. It may be an option for people at higher risk for lung problems or those with early breathing issues after surgery.
São Paulo, São PauloAges 18 years+ - NCT06921681Recruiting
Ultrasound-guided biopsy of chest lymph nodes
This trial uses a special ultrasound-guided procedure to take tissue samples from swollen lymph nodes in the chest. It aims to improve diagnosis for people who already need a bronchoscopy.
BaselAges 18–90 - NCT06919380RecruitingPhase 1
Mist from stem cell byproducts for autoimmune lung disease
This study tests a new type of treatment using a mist (nebulized) made from stem cell byproducts to see if it can safely help people with a rare autoimmune lung disease. It is for patients with anti-MDA5 positive dermatomyositis who have a fast-progressing lung condition.
Guangzhou, GuangdongAges 18–75 - NCT06926413RecruitingPhase 1
How aumolertinib changes midazolam levels in lung cancer patients
This study tests how a lung cancer pill called aumolertinib affects the levels of another drug (midazolam) in your body. It is for people with advanced NSCLC whose tumors have specific EGFR gene changes.
Hangzhou, ZhejiangAges 18 years+ - NCT07206498RecruitingPhase 1/Phase 2
Study of WSD0922-FU with Osimertinib for advanced NSCLC
This trial tests a new combination treatment (WSD0922-FU plus osimertinib) for people with advanced non-small cell lung cancer (NSCLC) that has a specific EGFR mutation. The goal is to see if the combination is safe and effective.
ShanghaiAges 18 years+ - NCT07211529Recruiting
Nerve block during chest surgery to reduce complications
This trial tests whether a numbing injection near the spine (paravertebral block) given during keyhole chest surgery can lower the risk of problems after surgery. It might help patients recover more comfortably.
Wuhan, HubeiAges 18–80
Hear when a new Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung?
- Yes. Clin2 currently lists 2,828 recruiting lung studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.